Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02482233 · ClinicalTrials.gov registry record · Phase 4
The END Perioperative Smoking Pilot Study
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT02482233: Completed Phase 4 study, sponsored by University of California, San Francisco.
NCT02482233 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02482233, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this pilot randomized trial is to determine the feasibility of e-cigarettes and telephone counselling (compared to transdermal nicotine replacement and telephone counselling) as a harm-reduction tool that may lead to increased smoking cessation in the perioperative setting in smokers presenting for elective surgery at the San Francisco Veterans Affairs Medical Center. Secondary outcomes include acceptability of e-cigarettes over transdermal nicotine replacement, length-of-stay in the post-anesthesia care unit, hospital length-of-stay, postoperative complications within the first 30-days, and smoking status 8-weeks after randomization. This pilot study is designed to provide the preliminary data necessary to plan and fund a larger-scale randomized clinical trial that will assess the utility of e-cigarettes in achieving smoking cessation perioperatively. Our ultimate goal is to add to the limited existing data on the safety and efficacy of e-cigarette use in smoking cessation, specifically in the perioperative setting where the risks of continued smoking are great and the motivation to stop is high.
Primary Outcome
Confirmed abstinent. Abstinence confirmed with exhaled carbon monoxoide \<10ppm. Time Frame depends on date of preadmission clinic visit
Interventions
- BEHAVIORAL telephone counseling
- BEHAVIORAL ENDD (NJOY)
- DRUG NRT (NicoDerm CQ)
- BEHAVIORAL brief advice
- BEHAVIORAL brochure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-09 |
| Phase | Phase 4 |
What the finished NCT02482233 record still lists
NCT02482233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which telephone counseling is the first listed.
NCT02482233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02482233 about?
NCT02482233 is a clinical study titled "The END Perioperative Smoking Pilot Study". The purpose of this pilot randomized trial is to determine the feasibility of e-cigarettes and telephone counselling (compared to transdermal nicotine replacement and telephone counselling) as a harm-reduction tool that may lead to increased smoking cessation in the perioperative setting in smokers ...
What is the current status of trial NCT02482233?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2015-08. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02482233?
The interventions under investigation include: telephone counseling (BEHAVIORAL), ENDD (NJOY) (BEHAVIORAL), NRT (NicoDerm CQ) (DRUG), brief advice (BEHAVIORAL), brochure (BEHAVIORAL).
Who is sponsoring clinical trial NCT02482233?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02482233's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia